Onkologi SE

The combination of enzalutamide and Ra-223 as first-line therapy for patients with bone metastatic castration-resistant prostate cancer significantly improves rPFS. This improvement was supported by a significantly improved OS and also by a statistically significant improvement in time to next systemic treatment, Silke Gillessen concludes in this MEDtalk from the ESMO - European Society for Medical Oncology 2024 Congress in Barcelona. 🔗See more from ESMO24: https://lnkd.in/dPFWrSZF #ESMO24 #Prostatecancer

Professor Tony Mok, Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong, presents two outstanding lung cancer results from ASCO 2024 in this MEDtalk. He also gives his perspective on a new KRAS-G12C inhibitor based on the CRYSTAL-12 trial. 🔗 Read more about ASCO 2024 here: https://lnkd.in/dwzh7PVr #ASCO24 #LungCancer #Treatment

At this year’s ESMO congress, the long-awaited final overall survival in patients with newly diagnosed advanced ovarian cancer treated with the parp-inhibitor niraparib as first-line maintenance therapy was presented. In this MEDtalk, Mansoor Raza Mirza from Rigshospitalet in Denmark, presented the results of the PRIMA trial. He also perspectives the status of treatment of ovarian cancer with immunotherapy. 🔗 Read more about ESMO 2024 here: https://lnkd.in/dPFWrSZF #ESMO24 #OvarianCancer #Immunotherapy

Hear Andrea Botticelli present the primary results of the ROME trial in this MEDtalk from ESMO 2024. The study demonstrated that a mutational-based treatment approach based on the Molecular Tumor Board discussion of comprehensive genome profiling results may significantly improve ORR and PFS compared to standard of care in pretreated patients with metastatic solid tumors, particularly with immunotherapy. 🔗 Read more about ESMO 2024 here: https://lnkd.in/dPFWrSZF #ESMO24 #Immunotherapy #Tumor

Marco Donia moderated a press conference on immunotherapy at the 2024 ESMO - European Society for Medical Oncology congress . In this MEDtalk, he discusses significant updates on neoadjuvant treatments for stage 3 melanoma, where immunotherapy before surgery improves outcomes, mainly when a significant pathological response is achieved. 🔗See more from ESMO24: https://lnkd.in/dPFWrSZF #ESMO24 #Immunotherapy #Melanoma

Astrid Lahousse presents: This article explores the effect of psychologically informed practice with behavioral graded activity in cancer survivors. #Cancer #Therapy #QualityOfLife

In this MEDtalk, Elisabeth Beisland presents two systematic reviews of cancer patients over 80 with a focus on quality of life and symptoms. The studies found very limited evidence on this group of patients, which underlines the urgent need for more knowledge. Not least in a future where the population of elderly people with cancer is growing. 🔗 Read more about ESMO 2024 here: https://lnkd.in/dPFWrSZF #ESMO24 #Cancer #QualityOfLife

The first results from the ProBio study show that treatment with ARPI leads to longer PFS, but Henrik Grönberg predicts that there will be many larger publications and results from the study in the future. 🔗 Read more about ESMO 2024 here: https://lnkd.in/dPFWrSZF #ESMO24 #ProstateCancer #ARPI

BestPractice Nordic presents: The Nordic countries, home to 27 million people, present a unique opportunity for advancing clinical research. The region's cohesive healthcare systems, shared challenges, and similar patient demographics allow for robust data collection, even from smaller patient populations, while ensuring high-quality, evidence-based research. #Breastcancer

In this MEDtalk from ESMO 2024, Dr Ingrid Dyvik from Oslo University Hospital presents findings from the IMPRESS-Norway trial. This trial evaluates the efficacy of anti-cancer drugs in new indications. Dyvik highlights the role of circulating tumour DNA (ctDNA) in precision oncology. 🔗 Read more about ESMO 2024 here: https://lnkd.in/dPFWrSZF #ESMO24 #Cancer #DNA